{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:57:34Z","timestamp":1790539054168,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinthera.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:37:32Z","timestamp":1782819452000},"page":"1030-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults"],"prefix":"10.1016","volume":"48","author":[{"given":"Alanna","family":"McEneny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Amancha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Easton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacc\u00e0","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0002","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0003","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1526317","article-title":"The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?","volume":"16","author":"Michailidou","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11940-024-00783-w","article-title":"A new era in the treatment of myasthenia gravis: six new medications in the last 6 years","volume":"26","author":"Patel","year":"2024","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clinthera.2026.06.001_sbref0009","series-title":"Soliris (Eculizumab). Prescribing Information","year":"2025"},{"key":"10.1016\/j.clinthera.2026.06.001_sbref0010","series-title":"Ultomiris (Ravulizumab). Prescribing Information","year":"2025"},{"key":"10.1016\/j.clinthera.2026.06.001_sbref0011","series-title":"Zilbrysq (Zilucoplan). Prescribing Information","year":"2026"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0013","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0016","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70158","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0019","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review","volume":"8","author":"Stoner","year":"2015","journal-title":"Patient"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0020","first-page":"55","article-title":"Eliciting exploratory patient preference data: a case study in a rare disease","volume":"38","author":"Ho","year":"2024","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70081","article-title":"Patient and care partner perspectives and preferences related to myasthenia gravis treatment: a qualitative study","volume":"7","author":"Yung","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0022","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1007\/s12325-023-02671-2","article-title":"The adherence and outcomes benefits of using a connected, reusable auto-injector for self-injecting biologics: a narrative review","volume":"40","author":"Antalfy","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.molimm.2023.12.004","article-title":"Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration","volume":"165","author":"Jindal","year":"2024","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0024","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0025","unstructured":"National Institutes of Health. Safety and efficacy of ALXN1720 in adults with generalized myasthenia gravis. https:\/\/clinicaltrials.gov\/study\/NCT05556096. Accessed May 5, 2026."},{"key":"10.1016\/j.clinthera.2026.06.001_bib0026","unstructured":"National Institutes of Health. PK, PD, safety, and efficacy study of gefurulimab in pediatric patients with AChR+ generalized myasthenia gravis. https:\/\/clinicaltrials.gov\/study\/NCT06607627. Accessed May 5, 2026."},{"key":"10.1016\/j.clinthera.2026.06.001_bib0027","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed May 5, 2026."},{"key":"10.1016\/j.clinthera.2026.06.001_bib0028","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations. 2014. https:\/\/www.fda.gov\/media\/88254\/download. Accessed May 5, 2026."},{"key":"10.1016\/j.clinthera.2026.06.001_bib0029","series-title":"Presented at: American Academy of Neurology (AAN) Annual Meeting; April 22-27","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ALXN1720 in healthy volunteers: a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study","author":"Ortiz","year":"2023"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clinthera.2020.11.014","article-title":"Tezepelumab pharmacokinetics, safety, and tolerability after administration via vial-and-syringe, accessorized prefilled syringe, or autoinjector: a randomized trial in healthy volunteers","volume":"43","author":"Zheng","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0031","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clinthera.2021.01.009","article-title":"Pharmacokinetic comparability of risankizumab formulations in prefilled syringe and auto-injector for subcutaneous injection","volume":"43","author":"Lon","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0032","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1007\/s12325-025-03335-z","article-title":"Pharmacokinetic bridging between an autoinjector and a prefilled syringe following subcutaneous administration of mirikizumab in healthy participants","volume":"42","author":"Zhang","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0033","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2021.06.038","article-title":"Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins","volume":"336","author":"Zou","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0034","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/02770903.2019.1663428","article-title":"Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results","volume":"58","author":"Martin","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.clinthera.2026.06.001_bib0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/12034754231188444","article-title":"A systematic review and meta-analysis of injection site reactions in randomized-controlled trials of biologic injections","volume":"27","author":"Kim","year":"2023","journal-title":"J Cutan Med Surg"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:26:51Z","timestamp":1790537211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0149291826001906"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}